Skip to main content
Premium Trial:

Request an Annual Quote

Response Biomedical Seeks to Raise $9.5M

NEW YORK (GenomeWeb News) – Response Biomedical has filed a prospectus to sell 73,333,333 units at a price of C$.15 per unit for gross proceeds of around C$11 million (US$9.5 million).

Each unit will consist of one common share and one-half of one common share purchase warrant. Each whole warrant will enable the holder to purchase one additional common share at a price of C$.25 for a period of 24 months from the closing date of the offering, which is expected on or around May 21, said Response Biomedical.

The Vancouver, BC-based genetic test maker also granted the underwriter of the offering an over-allotment option to purchase an additional 11 million units at the offering price.

Response Biomedical's shares closed at C$.15 yesterday on the Toronto Stock Exchange.

Filed under

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.